About Us


Recent Headlines

Sonoran Biosciences  |  1475 N. Scottsdale Rd. Suite 200  |  Scottsdale, AZ 85257  |  P: 480-389-6413

© 2018 Sonoran Biosciences, Inc.


Sonoran Biosciences is a preclinical stage pharmaceutical company that has developed SB Gel, a novel viscous sustained release carrier. SB Gel enables sustained release of a wide variety of drugs to new sites in the body, including irregular surgical sites and device surfaces. We develop new formulations using approved active ingredients, requiring reduced development cost and risk while retaining the exclusivity of a typical pharmaceutical. Formulations based on SB Gel have potential in a number of therapeutic areas including infection and pain management. Our lead product, SBG002, is a fixed-dose combination of tobramycin and vancomycin being developed for treatment of prosthetic joint infection.

Sonoran Biosciences welcomes three new Clinical Advisors.

Sonoran Biosciences is a presenting company at Biotech Showcase 2018.

Sonoran Biosciences has filed a new provisional patent application on improved formulation and stability of SB Gel platform.

Sonoran Biosciences has received a Phase 2 SBIR award from the National Institutes of Health for $1.48 million. Click to view the press release.